Results 71 to 80 of about 104,183 (265)
Fluorescent BODIPY‐conjugated thiosemicarbazone ligands and their Ga(III), In(III), and Fe(III) complexes, inspired by Triapine, are developed as theranostic agents. Multiphoton FLIM and confocal microscopy in cancer cells and zebrafish reveal real‐time uptake, mitochondrial localisation, and whilst spectroscopic assays indicated preserved complex ...
Megan J. Green +15 more
wiley +1 more source
MECHANISM OF APOPTOSIS INHIBITION TO SQUAMOUS CELL CARCINOMA OF ORAL CANCER IN CISPLATIN TREATMENT
This study was to approve the increased secretion of Hsp 70, DNA damage, and inhibitor apoptosis protein in cisplatin therapy which influence apoptosis of oral cancer cell and to know mechanism of molecular pathology.
R Marjono Dwi Wibowo +2 more
doaj +1 more source
ABSTRACT Breast cancer remains one of the most prevalent malignancies among women, and taxane‐based chemotherapies such as paclitaxel and docetaxel are central to standard treatment regimens. However, drug resistance in breast cancer limits therapeutic efficacy and contributes to recurrence and metastasis.
Kai Wang +7 more
wiley +1 more source
FGF13 is upregulated in DRG neurons of PIPNP model mice. DRG neuron‐specific knockout of FGF13 ameliorates PIPNP symptoms. Mechanistically, FGF13 potentiates microtubule detyrosination by promoting VASH1 binding to microtubules. FGF13 knockout suppresses VASH1‐mediated microtubule detyrosination and promotes α‐tubulin tyrosination.
Yiming Dong +10 more
wiley +1 more source
Mingzhe Zhu,1,* Lei Yang,2,* Xin Wang3 1Department of Obstetrics and Gynecology, Jilin Medical College Affiliated Hospital, Jilin City, Jilin Province 132011, People’s Republic of China; 2Department of Medical Clinic, Yuhuangding Hospital, Yantai ...
Zhu M, Yang L, Wang X
doaj
Cisplatin resistance and opportunities for precision medicine
Cisplatin is one of the most commonly used chemotherapy drugs, treating a wide range of cancer types. Unfortunately, many cancers initially respond to platinum treatment but when the tumor returns, drug resistance frequently occurs. Resistance to cisplatin is attributed to three molecular mechanisms: increased DNA repair, altered cellular accumulation,
openaire +2 more sources
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang +6 more
wiley +1 more source
This study identifies SNRPF as a critical oncogenic driver in ovarian cancer. By regulating a self‐sustaining SNRPF–DDX24–E2F4 feedback loop through intron retention and nonsense‐mediated decay, SNRPF couples RNA splicing with transcriptional regulation to promote tumor progression.
Yingwei Li +4 more
wiley +1 more source
Mitochondrial SLC25A46 is upregulated in ovarian cancer (OC) and correlates with poor prognosis. SLC25A46 stabilizes CACT to activate fatty acid oxidation, increasing ATP and NADPH production to drive cell proliferation and ferroptosis evasion. SLC25A46 silencing sensitizes OC cells to ferroptosis and carboplatin, offering a promising therapeutic ...
Yunge Gao +9 more
wiley +1 more source
Radioresistance severely limits the efficacy of therapies for small cell lung cancer (SCLC). This study reveals a novel mechanism of resistance driven by the active suppression of pyroptosis. Specifically, the mTORC2 complex directly phosphorylates GSDME‐N and promotes its CUL4B‐mediated ubiquitination and proteasomal degradation.
Qing‐qing Xu +11 more
wiley +1 more source

